Refine by
Lupus Erythematosus Articles & Analysis: Older
19 news found
Also based on the positive results in psoriasis patients, we presented our development plan for ‘3667, confirming the start of a Phase 2 study in dermatomyositis (GALARISSO) around year-end and the intention to start a Phase 2 study in systemic lupus erythematosus (SLE) in 2023. We also presented an update on our SIKi portfolio, a potential novel ...
For those who have recently suffered from vitiligo, psoriasis, systemic lupus erythematosus, and have undergone chemical peeling, grinding and other skin resurfacing procedures , Those who use retinoic acid drugs in the near future need to seriously inquire about the records, and inform them of possible risks, so as to avoid medical disputes caused by factors ...
The other assets are two previously licensed candidates and three new immune-oncology therapeutic candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. The agreement includes a $1m upfront payment with RubrYc's investors also eligible to receive up to $5m in development ...
New Therapeutic Candidates: Three promising immuno-oncology candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. Purchase terms include: An upfront payment of $1 million in iBio’s common stock to RubrYc investors. ...
(NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in ...
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment response to LUPKYNIS with reductions in ...
ERA Congress 2022 Presentations: Title: “Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study” Presenting author: Y.K. ...
(NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. ...
“Aurinia is committed to expanding the body of research supporting the clinical benefits of LUPKYNIS, the first FDA-approved oral therapy available to people living with lupus nephritis,” said Neil Solomons, M.D., Chief Medical Officer at Aurinia. ...
The multi-cytokines detectable by Creative Proteomics include but are not limited to the following: (1) Cancer Cytokines Assay (2) Cytokine Storm Assays (3) Autoimmune Disease Cytokines Assay (4) Inflammation Cytokines Assay (5) Rheumatoid Arthritis Cytokines Assay (6) Atopic Dermatitis Cytokines Assay (7) Osteoporosis Cytokines Assay (8) Apoptosis ...
Equillium is also conducting a Proof of Concept study for its use in systemic lupus erythematosus (SLE) / lupus nephritis (LN) and has expanded its EQUALISE phase 1b study to clinical centres in India. ...
ByBiocon
The expansion builds on the collaboration initiated in 2019 and adds systemic lupus erythematosus (SLE) and heart failure (HF) to ongoing work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). ...
Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines and proteins through a variety of technologies. Systemic lupus erythematosus is a typical systemic autoimmune disease characterized by the loss of autoimmune tolerance and ...
(NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious ...
(NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic ...
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and ...
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? ...
In addition to rheumatoid arthritis (RA) where the largest body of 14-3-3η data exists, conditions such as System Lupus Erythematosus, Inflammatory Bowel Disease and Psoriasis have a high incidence of arthritis, secondary to their primary autoimmune disease. 14-3-3η informs mechanistic joint damage processes common to these conditions allowing novel ...
Mount Tam's most advanced product focuses on the treatment of systemic lupus erythematosus (SLE), the most common form of lupus. By working with scientists from research institutes and universities around the globe, US Equity Holdings recognizes that it can help to provide the benefits not only of an innovation-focused culture, but also of ...